Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...